Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DTYMK | P23919 | 4/20 | 0.58 |
| ▸ | TERT | O14746 | 2/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | TK1 | P04183 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26220865 | 1.00 | DTYMK (0.58) | DTYMKTERTF2TK1POLB | |
| SCHEMBL26488937 | 1.00 | DTYMK (0.58) | DTYMKTERTF2TK1POLB | |
| SCHEMBL27062429 | 1.00 | DTYMK (0.58) | DTYMKTERTF2TK1POLB | |
| SCHEMBL27062409 | 1.00 | DTYMK (0.58) | DTYMKTERTF2TK1POLB | |
| SCHEMBL18159196 | 0.96 | DTYMK (0.54) | DTYMKTERTF2TK1POLB | |
| SCHEMBL18472073 | 0.96 | DTYMK (0.54) | DTYMKTERTF2TK1POLB | |
| SCHEMBL17775306 | 0.96 | DTYMK (0.54) | DTYMKTERTF2TK1POLB | |
| SCHEMBL20024801 | 0.96 | DTYMK (0.54) | DTYMKTERTF2TK1POLB | |
| SCHEMBL26220953 | 0.96 | DTYMK (0.54) | DTYMKTERTF2TK1POLB | |
| SCHEMBL27103956 | 0.96 | DTYMK (0.54) | DTYMKTERTF2TK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357779-A1 | COMPOUNDS AND METHODS FOR REDUCING IFNAR1 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11753644-B2 | Compounds and methods for reducing IFNAR1 expression | IONIS PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753644-B2 | Compounds and methods for reducing IFNAR1 expression | IFNAR1, STING1, IRF3 | DTYMK 1649/4885TERT 3730/4885F2 3645/4885 |
| US-20230357779-A1 | COMPOUNDS AND METHODS FOR REDUCING IFNAR1 EXPRESSION | IFNAR1, STING1, IRF3 | DTYMK 1822/4885TERT 3635/4885F2 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.